Clinical Trials
11 trialsNCT07575412 2026-05-08
SHR2554/AZA + Overlapped Modified BUCY for High-risk/Relapsed Leukemia/MDS
The First Affiliated Hospital of Soochow University
Phase 2 Not yet recruiting
NCT07301424 2026-05-06
Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL+ B-ALL
University of Alberta
Phase 2 Not yet recruiting
NCT07178912 2026-05-05
Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)
M.D. Anderson Cancer Center
Phase 2 Not yet recruiting
NCT07192237 2026-05-05
Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Patients With Measurable Residual Disease Positive B-cell Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 2 Not yet recruiting
NCT07562568 2026-05-01
SHR2554/AZA + Overlapped TBF for High-risk/Relapsed Leukemia/MDS
The First Affiliated Hospital of Soochow University
Phase 2 Not yet recruiting
NCT05565105 2026-03-03
CD34+ Transplants for Leukemia and Lymphoma
Baptist Health South Florida
Phase 2 Not yet recruiting
NCT07301138 2025-12-24
BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients
Ruijin Hospital
Phase 2 Not yet recruiting
NCT07227584 2025-11-12
ALL Backbone in AYAs
Dana-Farber Cancer Institute
Phase 2 Not yet recruiting
NCT06930105 2025-08-06
Impact of Low-intensity Chemotherapy Combined With Short-course Blinatumomab on Allo-HSCT in Adults With Ph- B-ALL
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2 Not yet recruiting
NCT06861348 2025-03-06
ZJU-HSCT-INO
First Affiliated Hospital of Zhejiang University
Phase 2 Not yet recruiting
NCT06777264 2025-01-15
JUVENTAS-ALL05
First Affiliated Hospital of Zhejiang University
Phase 2 Not yet recruiting